Tellimer
  • Quarterly result recovery forecast in 2Q21 and strong 2H21outlook
  • Value accretion in three recent deals becomes meaningful in 2022
  • Building global plant-based food platform

Share price deserves rally ahead of quick strong earnings recovery seen in 2Q21 and growth of plant-based food business. We rolled investment horizon to a YE22 DCF-derived target price of Bt11.20 (7.6% WACC and 2.5% terminal growth). With high growth profile, PER is easing from 55.4x in 2021 to 48.3x in 2022. BUY!

Quarterly result recovery forecast in 2Q21 and strong 2H21outlook

A nadir quarterly result was seen in 1Q21. We preliminary forecast core profit growth of about 40-45% YoY and QoQ in 2Q21. Given stable SG&A expenses, record sales forecast in 2Q21 (a jump of about 60% YoY and 10% QoQ) will drive economies of scale benefits. All-time high sales in 2Q21 are driven by delayed shipments of ethnic sales (up QoQ by 10%), e-commerce sales given full quarter contribution of Prime Labs, functional product sales, and plant-based food. GM would sustain high QoQ at 32.5%, up 170bps YoY. In 2H21, performances are heading to high seasonality, as sales would increase by 30% YoY and 10% HoH. We expect record sales to continue in 3Q21 and 4Q21. Plant-based food business in UK is reaffirmed to turnaround in 2H21.  Revenue from terpene flavored product and hemp is expected in 4Q21.  


Most Viewed See latest
Disclosures

This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not con...

Full Tellimer disclaimers